Literature DB >> 20532778

Spontaneous regression of multiple pulmonary metastases after radiofrequency ablation of a single metastasis.

Pramod Rao1, Bernard Escudier, Thierry de Baere.   

Abstract

We report two cases of spontaneous regression of multiple pulmonary metastases occurring after radiofrequency ablation (RFA) of a single lung metastasis. To the best of our knowledge, these are the first such cases reported. These two patients presented with lung metastases progressive despite treatment with interleukin-2, interferon, or sorafenib but were safely ablated with percutaneous RFA under computed tomography guidance. Percutaneous RFA allowed control of the targeted tumors for >1 year. Distant lung metastases presented an objective response despite the fact that they received no targeted local treatment. Local ablative techniques, such as RFA, induce the release of tumor-degradation product, which is probably responsible for an immunologic reaction that is able to produce a response in distant tumors.

Entities:  

Mesh:

Year:  2010        PMID: 20532778     DOI: 10.1007/s00270-010-9896-9

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  14 in total

1.  Pre-resectional Radiofrequency Ablation as a Neoadjuvant in situ Tumor Vaccine.

Authors:  Fumito Ito; Sharon S Evans
Journal:  J Vaccines Vaccin       Date:  2016-03-09

Review 2.  Focused ultrasound: tumour ablation and its potential to enhance immunological therapy to cancer.

Authors:  Giovanni Mauri; Luca Nicosia; Zhen Xu; Salvatore Di Pietro; Lorenzo Monfardini; Guido Bonomo; Gianluca Maria Varano; Francesco Prada; Paolo Della Vigna; Franco Orsi
Journal:  Br J Radiol       Date:  2018-01-17       Impact factor: 3.039

Review 3.  Postablation Immune Microenvironment: Synergy between Interventional Oncology and Immuno-oncology.

Authors:  DaeHee Kim; Joseph P Erinjeri
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

Review 4.  Percutaneous image-guided cryoablation: current applications and results in the oncologic field.

Authors:  Roberto Luigi Cazzato; Julien Garnon; Nitin Ramamurthy; Guillaume Koch; Georgia Tsoumakidou; Jean Caudrelier; Francesco Arrigoni; Luigi Zugaro; Antonio Barile; Carlo Masciocchi; Afshin Gangi
Journal:  Med Oncol       Date:  2016-11-11       Impact factor: 3.064

Review 5.  Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.

Authors:  Joseph P Erinjeri; Gabriel C Fine; Gosse J Adema; Muneeb Ahmed; Julius Chapiro; Martijn den Brok; Rafael Duran; Stephen J Hunt; D Thor Johnson; Jens Ricke; Daniel Y Sze; Beau Bosko Toskich; Bradford J Wood; David Woodrum; S Nahum Goldberg
Journal:  Radiology       Date:  2019-04-23       Impact factor: 11.105

6.  Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study.

Authors:  Jiang Long; Jia-sheng Zheng; Bin Sun; Ningning Lu
Journal:  Hepatol Int       Date:  2016-01-07       Impact factor: 6.047

7.  Freezing Fort Knox: Mesenteric Carcinoid Cryoablation.

Authors:  Erik Soule; Arya Bagherpour; Jerry Matteo
Journal:  Gastrointest Tumors       Date:  2017-08-31

Review 8.  Systematic review of ablation techniques for the treatment of malignant or aggressive benign lesions in children.

Authors:  Fernando M Gómez; Premal A Patel; Samuel Stuart; Derek J Roebuck
Journal:  Pediatr Radiol       Date:  2014-05-13

Review 9.  Local Destruction of Tumors and Systemic Immune Effects.

Authors:  Karl-Göran Tranberg
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

10.  Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation.

Authors:  Jiaqiang Dan; Yaojun Zhang; Zhenwei Peng; Junting Huang; Hengjun Gao; Li Xu; Minshan Chen
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.